GlassScriptPhysician profile
Philip D Leming
NPI 1679569842
$7,308.17
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $2,542 · 2021: $2,676 · 2022: $353 · 2023: $217 · 2024: $458 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,651.86 | 2019-2025 | Libtayo |
| Array Biopharma INC | $2,601.77 | 2019-2023 | Xalkori, Braftovi, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $385.36 | 2019-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $238.02 | 2019-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $194.33 | 2023-2025 | |
| Immunocore Limited | $138.39 | 2023-2024 | Kimmtrak |
| Tempus Ai, INC | $127.04 | 2024 | |
| Astellas Pharma US INC | $96.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.49 | 2019 | |
| Daiichi Sankyo INC. | $96.30 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $87.94 | 2024-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $73.37 | 2019-2022 | |
| Janssen Biotech, INC. | $58.46 | 2024-2025 | Rybrevant |
| Genzyme Corporation | $56.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.56 | 2019-2024 | Iclusig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.64 | 2019 | |
| Foundation Medicine, INC. | $38.88 | 2019 | |
| Iovance Biotherapeutics, INC. | $35.15 | 2025 | Amtagvi |
| Celgene Corporation | $33.56 | 2019 | |
| Aveo Pharmaceuticals, INC. | $31.70 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $24.88 | 2019 | |
| Eisai INC. | $24.28 | 2019 | |
| Blueprint Medicines Corporation | $18.83 | 2022 | |
| Tolmar, INC. | $17.19 | 2024 | |
| Progenics Pharmaceuticals, INC. | $16.22 | 2024 | |
| Mylan Institutional INC. | $15.68 | 2019 | |
| Puma Biotechnology, INC. | $15.67 | 2019 | |
| Abbvie INC. | $14.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.44 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Leming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.